Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Medicine
Vitamin B3 Strategy Shows Early Signal in Glioblastoma Trial
University of Calgary researchers are testing controlled-release niacin alongside standard glioblastoma treatment, with early Phase I/II results suggesting immune-cell effects and better-than-expected six-month disease control.
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
ScienceDaily reported on 22 June 2026 that University of Calgary researchers are studying whether high doses of vitamin B3, also known as niacin, can improve outcomes when added to standard glioblastoma treatment.
Glioblastoma remains one of the most aggressive adult brain cancers. Standard care typically includes surgery, radiotherapy and chemotherapy, yet recurrence is common and survival gains have been difficult to sustain.
The Calgary program grew from laboratory work suggesting niacin could restore weakened immune-cell function and help those cells attack tumor cells. The human trial is designed to identify the highest safe dose and test controlled-release niacin with chemotherapy and radiotherapy.
The report says the team set a stopping benchmark before the trial: six-month progression-free survival needed to improve by at least 20 percent compared with previous studies. Early findings from 24 patients exceeded that threshold, with 82 percent showing no disease progression at six months.
Why It Matters
This is not a cure and not a self-treatment signal. It is an early clinical result in a carefully monitored trial. The important point is that a low-cost molecule may be affecting the tumor immune environment, which could open a practical adjunct route if the final dataset holds up.
Sourcing note: The early patient numbers and trial framing come from University of Calgary materials reported by ScienceDaily. Researchers explicitly warn that high-dose vitamins can be toxic and require medical monitoring.
Why It Matters
The result is early, but glioblastoma has had limited therapeutic progress for decades. A monitored adjunct strategy that reawakens immune activity would be clinically meaningful if confirmed in the full trial.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
GlioblastomaVitamin B3Clinical TrialsCancer Immunology